

For postmenopausal women  
with a recent osteoporotic fracture,<sup>1</sup>

## TYMLOS was designed with patients in mind

Administered through a  
disposable, 5- to 8-mm,  
31-gauge needle<sup>1\*</sup>

One 156-mL pen  
contains 30 days  
of **80-mcg** doses<sup>1</sup>

Studied as an  
18-month course  
of therapy<sup>1</sup>



Injection site should  
be rotated and dose  
should be injected at  
approximately the same  
time each day into the  
periumbilical region of  
the abdomen, with or  
without food or drink<sup>1</sup>

Before first use,  
store TYMLOS  
in a refrigerator  
between 36°F to  
46°F. After first use,  
no refrigeration is  
required for up to  
30 days (between  
68°F to 77°F)<sup>1</sup>

Cumulative use  
of TYMLOS and  
parathyroid hormone  
analogues (e.g.,  
teriparatide) for more  
than 2 years during  
a patient's lifetime  
is not recommended<sup>1</sup>

\*Pen needles are not included.

► See inside for storage information

### IMPORTANT SAFETY INFORMATION WARNING: RISK OF OSTEOSARCOMA

- Abaloparatide caused a dose-dependent increase in the incidence of osteosarcoma (a malignant bone tumor) in male and female rats. The effect was observed at systemic exposures to abaloparatide ranging from 4 to 28 times the exposure in humans receiving the 80 mcg dose. It is unknown if TYMLOS will cause osteosarcoma in humans.
- The use of TYMLOS is not recommended in patients at increased risk of osteosarcoma including those with Paget's disease of bone or unexplained elevations of alkaline phosphatase, open epiphyses, bone metastases or skeletal malignancies, hereditary disorders predisposing to osteosarcoma, or prior external beam or implant radiation therapy involving the skeleton.
- Cumulative use of TYMLOS and parathyroid hormone analogues (e.g., teriparatide) for more than 2 years during a patient's lifetime is not recommended.

Please see Full Prescribing Information,  
including Boxed Warning, in pocket.

## How to store TYMLOS, a once-daily subcutaneous injection within a prefilled pen<sup>1</sup>

Storage and handling <sup>1</sup>	
Storage before first use	Storage after first use
<p>Store in a refrigerator between 36°F and 46°F (2°C and 8°C) at all times.</p> <p>Do not freeze or subject to heat.</p>	<p>Store for up to 30 days without refrigeration at a temperature between 68°F and 77°F (20°C and 25°C).</p> <p>Do not freeze or subject to heat.</p> <p>Store with pen cap on.</p> <p>Do not store with needle attached.</p>
Until expiration date	30 days



After first use, TYMLOS can be stored for up to 30 days **without refrigeration** (between 68° F and 77° F), unlike Forteo®, which should be stored under refrigeration at all times<sup>1,2</sup>

## How to write a prescription for TYMLOS

FOR _____	DATE _____
ADDRESS _____	
<b>R<sub>x</sub></b>	REFILL _____ TIMES
<p><b>TYMLOS® PEN</b></p> <p><b>INJECT 80 MCg SC DAILY, 1.56-ML PEN,</b></p> <p><b>DISPENSE #3, 3 REFILLS</b></p>	
PRODUCT SELECTION PERMITTED	DISPENSE AS WRITTEN
DEA NO. _____	ADDRESS _____

The TYMLOS pen is compatible with a variety of 31-gauge, 5- to 8-mm needle types<sup>1\*</sup>

These include:

- Clickfine®
- BD Ultra-Fine™
- MedtFine®
- Easy comfort
- Clever Choice™ Comfort EZ™
- SureComfort™

\*Pen needles are not included.

### IMPORTANT SAFETY INFORMATION (cont'd)

**Orthostatic Hypotension:** Orthostatic hypotension may occur with TYMLOS, typically within 4 hours of injection. Associated symptoms may include dizziness, palpitations, tachycardia or nausea, and may resolve by having the patient lie down. For the first several doses, TYMLOS should be administered where the patient can sit or lie down if necessary.

**Hypercalcemia:** TYMLOS may cause hypercalcemia. TYMLOS is not recommended in patients with pre-existing hypercalcemia or in patients who have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, because of the possibility of exacerbating hypercalcemia.

**Hypercalciuria and Urolithiasis:** TYMLOS may cause hypercalciuria. It is unknown whether TYMLOS may exacerbate urolithiasis in patients with active or a history of urolithiasis. If active urolithiasis or pre-existing hypercalciuria is suspected, measurement of urinary calcium excretion should be considered.

**Adverse Reactions:** The most common adverse reactions (incidence ≥2%) are hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain and vertigo.

**Please see Full Prescribing Information, including Boxed Warning, in pocket.**

## Together with Tymlos, a Patient Support Program

Upon enrollment:



You and your patients will be **assigned a case manager** to investigate benefits, help navigate prior authorization and/or appeals, and discuss financial support options



Patients will be connected to an **in-network specialty pharmacy** based on their coverage

Once approved:



The **Clinical Educator Network** helps patients with injection training and support as they start and stay on TYMLOS as directed by you

To download additional resources, visit

**[TYMLOShcp.com/resources-for-your-office](https://TYMLOShcp.com/resources-for-your-office)**

### INDICATIONS AND USAGE

TYMLOS is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, TYMLOS reduces the risk of vertebral fractures and nonvertebral fractures.

#### Limitations of Use

Because of the unknown relevance of the rodent osteosarcoma findings to humans, cumulative use of TYMLOS and parathyroid hormone analogs (e.g., teriparatide) for more than 2 years during a patient's lifetime is not recommended.

**Please see Full Prescribing Information, including Boxed Warning, in pocket.**

**References:** 1. TYMLOS<sup>®</sup> [prescribing information]. Waltham, MA: Radius Health, Inc; 2018. 2. Forteo<sup>®</sup> [prescribing information]. Indianapolis, IN: Lilly USA, LLC; 2017.

TYMLOS is a registered trademark of Radius Health, Inc.

All other trademarks are the property of their respective owners.

© 2018 Radius Health, Inc. All rights reserved. 12/18. TYM-US-02270